New blood test could predict which colorectal cancer patients benefit from targeted drugs
NCT ID NCT07224841
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to develop a blood test that uses epigenetic markers (chemical changes on DNA) to predict whether a patient with metastatic colorectal cancer will respond to targeted therapies like cetuximab or bevacizumab. Researchers will analyze blood samples from 500 patients before treatment to identify patterns that separate responders from non-responders. The goal is to create a tool that helps doctors personalize treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cfDNA 5mC/5hmC sequencing and assay
What this could lead to
If successful, this could lead to a simple blood test that helps doctors choose the right targeted therapy for each patient with metastatic colorectal cancer, improving treatment outcomes.
What could go wrong
This is an early-stage study focused on developing and validating a biomarker panel. The test may not prove accurate enough in larger populations, and it does not directly treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••